Bayer share price analyst price target raised UBS Goldman Sachs, Digi Mart USA News: UBS has raised its price target for Bayer from 62 to 66 euros, according to media reports published on Tuesday. The bank maintained its “Buy” rating.
Bayer shares fell 0.7% on Friday.
Goldman Sachs also raised its target, according to media reports, lifting it from 63.50 euros to 66.00 euros on Wednesday. The firm kept its “Buy” rating as well.
Bayer reported group sales of 10.053 billion euros for the third quarter of 2026 on Tuesday, a nominal increase of 4.1 percent. Adjusted for currency and portfolio effects, sales rose 1.9 percent, according to the company.
EBITDA before special items reached 1.615 billion euros in the same quarter, 6.9 percent higher. On Tuesday, Bayer also raised its 2026 outlook for both EBITDA before special items and free cash flow.
On Wednesday, Bayer received approval in China for sevabertinib. According to the company, the National Medical Products Administration (NMPA) approved the drug as a first-line treatment for adults with HER2-mutated non-small cell lung cancer.
The approval covers unresectable, locally advanced or metastatic disease.
In glyphosate litigation, Bayer reported on October 29 a decision in favor of Monsanto, after a jury in Missouri unanimously ruled for the company. Bayer said this was the first glyphosate trial since the U.S.
Supreme Court’s decision. The company said it is still awaiting a court ruling on the class settlement.
